| Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1) A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... Cancer discovery 7 (4), 400-409, 2017 | 837 | 2017 |
| Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1) Cancer … A Drilon, S Siena, SI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... Published by S. Karger AG, Basel www. karger. com/cro Gupta et al.: A …, 2019 | 144 | 2019 |
| EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung F Conforti, C Catania, F Toffalorio, M Duca, G Spitaleri, M Barberis, ... Lung Cancer 81 (3), 440-444, 2013 | 51 | 2013 |
| Phase I/IIa trial of BMS-986148, an anti-mesothelin antibody–drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors S Rottey, J Clarke, K Aung, JP Machiels, B Markman, KM Heinhuis, ... Clinical Cancer Research 28 (1), 95-105, 2022 | 43 | 2022 |
| Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy? A Tessari, L Pilla, D Silvia, M Duca, B Paolini, ML Carcangiu, L Mariani, ... The Breast 42, 68-73, 2018 | 37 | 2018 |
| Molecular tumor board as a clinical tool for converting molecular data into real-world patient care A Vingiani, L Agnelli, M Duca, D Lorenzini, S Damian, C Proto, M Niger, ... JCO Precision Oncology 7, e2300067, 2023 | 10 | 2023 |
| A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody–Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors M Duca, DWT Lim, V Subbiah, S Takahashi, J Sarantopoulos, A Varga, ... Molecular cancer therapeutics 21 (4), 625-634, 2022 | 10 | 2022 |
| Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy? M Ambrosini, G Fucà, M Duca, S Damian, F De Santis, F Corti, S Cresta, ... Critical Reviews in Oncology/Hematology 169, 103532, 2022 | 8 | 2022 |
| Phase I/II study of MAK683 in patients with advanced malignancies, including diffuse large B-cell lymphoma V Ribrag, JM Michot, L Igleias, D Tan, B Ma, M Duca, ZA Wainberg, ... Blood 138, 1422, 2021 | 8 | 2021 |
| 1525MO Phase I/II study of MAK683 in patients (pts) with advanced malignancies including epithelioid sarcoma R Bahleda, ZA Wainberg, A Spreafico, B Ma, V Subbiah, V Ribrag, ... Annals of Oncology 32, S1113-S1114, 2021 | 7 | 2021 |
| Pitfalls in oncology: a unique case of thoracic splenosis mimicking malignancy in a patient with resected breast cancer F Gelsomino, MR Castellani, A Marchianò, M Duca, P Mariani, G Aliberti, ... Journal of Thoracic Disease 8 (6), E403, 2016 | 6 | 2016 |
| Metastatic breast cancer treated with lapatinib with a prolonged benefit: a case report and a review of therapeutic options available GV Bianchi, M Duca, L Sica, G Mariani Tumori Journal 99 (6), e269-e272, 2013 | 6 | 2013 |
| A phase 1 study of mTORC1/2 inhibitor BI 860585 as a single agent or with exemestane or paclitaxel in patients with advanced solid tumors F de Braud, JPH Machiels, D Boggiani, SWH Rottey, M Duca, M Laruelle, ... Cancers 12 (6), 1425, 2020 | 5 | 2020 |
| Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1), Cancer … A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... CD-16-1237, 0 | 4 | |
| Abstract LB_A12: Initial results from 2 Phase I studies of NMS-03305293, a selective PARP1 inhibitor M Geurts, D Gramatzki, S Merler, M Duca, F Girardi, UT Sener, D Roberti, ... Molecular Cancer Therapeutics 22 (12_Supplement), LB_A12-LB_A12, 2023 | 3 | 2023 |
| Management of BRCA tumour testing in an integrated molecular tumour board multidisciplinary model J Azzollini, A Vingiani, L Agnelli, E Tamborini, F Perrone, E Conca, ... Frontiers in Oncology 12, 857515, 2022 | 3 | 2022 |
| Single Institution trial of anthracycline‐and taxane‐based chemotherapy for operable breast cancer: The ASTER study G Mariani, G Galli, S Cavalieri, P Valagussa, GV Bianchi, G Capri, ... The Breast Journal 25 (2), 237-242, 2019 | 3 | 2019 |
| Hyperprogression during immuno-checkpoint inhibitors (ICIs): A clinically significant problem? E Farè, S Sdao, S Damian, S Cresta, M Del Vecchio, M Di Bartolomeo, ... Annals of Oncology 29, viii430, 2018 | 3 | 2018 |
| Ascites during selpercatinib treatment: need for a multidisciplinary approach L Provenzano, S Damian, M Duca, S Della Valle, FGM De Braud Journal of Thoracic Oncology 18 (2), e9-e10, 2023 | 2 | 2023 |
| NMS-01940153E, an MPS1 inhibitor with anti-tumor activity in relapsed or refractory unresectable Hepatocellular carcinoma M Reig, S Damian, D Roberti, S Maruzzelli, P Crivori, L Gianellini, ... European Journal of Cancer 174, S2, 2022 | 2 | 2022 |
